Motoneuron Disease: Clinical (Q45869420)

17 December 2017

review article

1 reference

title

Motoneuron Disease: Clinical (English)

1 reference

17 December 2017

author name string

Hristelina Ilieva

series ordinal

1

1 reference

17 December 2017

Nicholas J Maragakis

series ordinal

2

1 reference

17 December 2017

publication date

1 January 2017

1 reference

17 December 2017

published in

Advances in neurobiology

1 reference

17 December 2017

volume

15

1 reference

17 December 2017

page(s)

191-210

1 reference

17 December 2017

Incidence of amyotrophic lateral sclerosis in Europe

cites work

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Prognostic factors in ALS: A critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

A revision of the El Escorial criteria - 2015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Natural history and clinical features of the flail arm and flail leg ALS variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Prognosis of amyotrophic lateral sclerosis with respiratory onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Study of 962 patients indicates progressive muscular atrophy is a form of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Prevalence and patterns of cognitive impairment in sporadic ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

The overlap of amyotrophic lateral sclerosis and frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Frontotemporal dementia: a bridge between dementia and neuromuscular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Hypermetabolism in ALS: correlations with clinical and paraclinical parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Energy metabolism in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Premorbid body mass index and risk of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Body mass index and dietary intervention: implications for prognosis of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Causes of death in a post-mortem series of ALS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Bipap improves survival and rate of pulmonary function decline in patients with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Early treatment with noninvasive positive pressure ventilation prolongs survival in Amyotrophic Lateral Sclerosis patients with nocturnal respiratory insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Noninvasive ventilation in ALS: indications and effect on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Nocturnal pulse oximetry: a new approach to establish the appropriate time for non‐invasive ventilation in ALS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidence-based review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

ALS patients on TPPV: totally locked-in state, neurologic findings and ethical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Predictors and course of elective long-term mechanical ventilation: A prospective study of ALS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Home ventilation for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family, and physician attitudes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Mechanical ventilation in amyotrophic lateral sclerosis: a cross-cultural perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Amyotrophic lateral sclerosis: the Midwestern surgical experience with the diaphragm pacing stimulation system shows that general anesthesia can be safely performed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

A randomized controlled trial of resistance exercise in individuals with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

pNfH is a promising biomarker for ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Use of biomarkers in ALS drug development and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Magnetic resonance imaging in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

What does imaging reveal about the pathology of amyotrophic lateral sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Cerebellar integrity in the amyotrophic lateral sclerosis-frontotemporal dementia continuum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Serotonin-1A receptors in frontotemporal dementia compared with controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

[11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

A clinical trial of verapamil in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Controlled trial of nimodipine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Phase II/III randomized trial of TCH346 in patients with ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Phase 2 study of sodium phenylbutyrate in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Lost in translation: treatment trials in the SOD1 mouse and in human ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

New considerations in the design of clinical trials for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

RNA-targeted Therapeutics for ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Antisense oligonucleotide therapy for neurodegenerative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Induced pluripotent stem cells from ALS patients for disease modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Extramotor involvement in ALS: PET studies with the GABAA ligand [11C]flumazenil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57193-5_7

10.1007/978-3-319-57193-5_7

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017